Serviks Adenokanseri Ön Tanısı Alan Hastada Nihai Patolojide Endometrial Kanser Tanısı: Olgu Sunumu
Özet
Endometrium kanseri, kadınlarda en sık görülen jinekolojik malignite olup, en sık görülen histolojik alt tip endometrioid adenokarsinomdur. Evre II hastalıkta servikal tutulum mevcuttur. 51 yaşında, postmenopozal hasta kliniğimize son 6 aydır olan düzensiz sıkılıkta olan vajinal kanama şikayeti ile başvurdu. Hastanın dış merkezde endometrium biyopsisi servikal kitle nedenli yapılamamış. Servikal biopsi patoloji sonucu servikal adenokarsinom olarak raporlandı. Hastanın preop görüntülemeleri amacıyla pelvik manyetik rezonans (MR) ve pozitron emisyon tomografisi (PET) tetkikleri planlandı. Radyolojik görüntüleme sonucunda hastaya operasyon kararı verildi. Nihai patoloji sonucu; Grade 3 endometrioid endometrium kanseri şeklinde raporlandı. Hastalığın evresi Evre II idi ve hastaya buna uygun adjuvan tedavi verildi. Bu sunum servikal malign lezyonların ayırıcı tanısında endometrial kanser invazyonunun dikkate alınması gerektiğini vurgulamaktadır.
Referanslar
Salehiniya, H., L. Allahqoli, and Z. Momenimovahed, Risk Factors for Endometrial Cancer in the World: A Narrative Review of the Recent Literature. Clinical and Experimental Obstetrics & Gynecology, 2024. 51(7): p. 169.
Morice, P., et al., Endometrial cancer. the Lancet, 2016. 387(10023): p. 1094-1108.
Liu, L., et al., Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. JNCI Cancer Spectrum, 2023. 7(1): p. pkad001.
Vetter, M.H., K. Bixel, and A.S. Felix, Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study. Journal of Gynecologic Oncology, 2020. 31(6): p. e84.
Shuai, X., et al., Type and approach of hysterectomy and oncological survival of women with stage II cancer of endometrium: a large retrospective cohort study. Frontiers in Oncology, 2024. 14: p. 1404831.
Randall, M.E., et al., Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer. Journal of Clinical Oncology, 2019. 37(21): p. 1810-1818.
De Boer, S.M., et al., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The lancet oncology, 2018. 19(3): p. 295-309.
Concin, N., et al., ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021. 31(1): p. 12-39.
Barakat, R.R., et al., Pelvic exenteration for recurrent endometrial cancer. Gynecologic oncology, 1999. 75(1): p. 99-102.
Creutzberg, C.L., et al., Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. The Lancet Oncology, 2024. 25(9): p. e420-e431.
Kalir, T., Molecular Characterization of Endometrial Cancers and Therapeutic Implications. 2025.
Nero, C., et al., POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort. Cancer, 2025. 131(3): p. e35731.
Corr, B., et al., Endometrial cancer: molecular classification and future treatments. BMJ medicine, 2022. 1(1): p. e000152.
Vicky, M., et al., Endometrial cancer (primer). Nature Reviews: Disease Primers, 2021. 7(1).
Abu-Rustum, N., et al., Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 2023. 21(2): p. 181-209.
Colombo, N., et al., ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. International Journal of Gynecological Cancer, 2016. 26(1): p. 2-30.
Fischerova, D., et al., The role of imaging in cervical cancer staging: ESGO/ESTRO/ESP guidelines (Update 2023). Cancers, 2024. 16(4): p. 775.
Chou, B., et al., Management of stage I and II cervical cancer: a review. International Journal of Gynecological Cancer, 2022. 32(3): p. 216-224.
